Clinical Scorecard: Oral spironolactone may hold edge in female acne
At a Glance
Category
Detail
Condition
Adult female acne; the review compares oral and topical spironolactone.
Key Mechanisms
The source reports clinical efficacy and systemic-exposure findings; it does not describe a specific mechanism of action.
Target Population
Primarily adult women with acne; some topical studies included mixed-sex cohorts or male volunteers.
Care Setting
Not specified in the source.
Key Highlights
Oral spironolactone had stronger supporting evidence than topical formulations for adult female acne, although efficacy could not be compared directly across studies.
In the 410-participant SAFA trial, acne-specific quality-of-life symptom scores favored spironolactone at 12 and 24 weeks; investigator-assessed treatment success at 12 weeks was 19% versus 6% with placebo. The primary-outcome difference at 12 weeks did not reach the 2-point difference the trial was powered to detect.
Topical studies reported lesion reductions, but evidence was limited by small samples, short follow-up, varied formulations and outcomes, and indirect applicability to adult women.
Reported oral adverse effects included menstrual irregularities and breast tenderness. Hyperkalemia was more frequent in women aged 46–65 years than in those aged 18–45 years in one retrospective study.
The review searched two databases, largely restricted eligibility to English-language publications, did not conduct a formal risk-of-bias assessment, and did not perform a meta-analysis.
